A decade of achievement in pulmonary hypertension Humbert M., Simonneau G., Rubin L.J. Eur Respir Rev 2011; 20: 215-217 | |
Systemic lupus erythematosus-associated PAH: is targeting inflammation the key to success? Foïs E., Sitbon O. Eur Respir Rev 2011; 20: 218-219 | |
A tribute: Abel Ayerza and pulmonary hypertension Mazzei J.A., Mazzei M.E. Eur Respir Rev 2011; 20: 220-221 | |
The value of tools to assess pulmonary arterial hypertension Gupta H., Ghimire G., Naeije R. Eur Respir Rev 2011; 20: 222-235 | |
Prognostic factors in pulmonary arterial hypertension: assessing the course of the disease Howard L.S. Eur Respir Rev 2011; 20: 236-242 | |
The role of the right ventricle in pulmonary arterial hypertension Vonk Noordegraaf A., Galiè N. Eur Respir Rev 2011; 20: 243-253 | |
Optimal management of severe pulmonary arterial hypertension Sitbon O., Simonneau G. Eur Respir Rev 2011; 20: 254-261 | |
Looking to the future: a new decade of pulmonary arterial hypertension therapy McLaughlin V.V. Eur Respir Rev 2011; 20: 262-269 | |
Risk factors associated with pulmonary arterial hypertension in patients with systemic sclerosis and implications for screening Denton C.P., Hachulla E. Eur Respir Rev 2011; 20: 270-276 | |
Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus Johnson S.R., Granton J.T. Eur Respir Rev 2011; 20: 277-286 | |
Asthma and suicide-related adverse events: a review of observational studies Iessa N., Murray M.L., Curran S., Wong I.C.K. Eur Respir Rev 2011; 20: 287-292 | |
The management of Eisenmenger syndrome in the modern treatment era: a case report Gatzoulis M.A. Eur Respir Rev 2011; 20: 293-296 | |
“Treat-to-target” in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation Hoeper M.M. Eur Respir Rev 2011; 20: 297-300 | |
Drug-induced eosinophilic pleural effusion Krenke R., Light R.W. Eur Respir Rev 2011; 20: 300-301 | |
Hunter's Diseases of Occupations. 10th Edition. Ameille J. Eur Respir Rev 2011; 20: 302 | |